BioArctic Valuation
| BIOA-B Stock | SEK 193.10 5.60 2.99% |
At this time, the firm appears to be overvalued. BioArctic AB shows a prevailing Real Value of kr149.98 per share. The current price of the firm is kr193.1. Our model approximates the value of BioArctic AB from analyzing the firm fundamentals such as Current Valuation of 26.19 B, profit margin of (0.05) %, and Return On Equity of -0.0142 as well as examining its technical indicators and probability of bankruptcy.
Overvalued
Today
Please note that BioArctic's price fluctuation is very steady at this time. Calculation of the real value of BioArctic AB is based on 3 months time horizon. Increasing BioArctic's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since BioArctic is currently traded on the exchange, buyers and sellers on that exchange determine the market value of BioArctic Stock. However, BioArctic's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 193.1 | Real 149.98 | Hype 193.1 | Naive 201.33 |
The real value of BioArctic Stock, also known as its intrinsic value, is the underlying worth of BioArctic AB Company, which is reflected in its stock price. It is based on BioArctic's financial performance, growth prospects, management team, or industry conditions. The intrinsic value of BioArctic's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of BioArctic AB helps investors to forecast how BioArctic stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of BioArctic more accurately as focusing exclusively on BioArctic's fundamentals will not take into account other important factors: BioArctic Total Value Analysis
BioArctic AB is currently estimated to have takeover price of 26.19 B with market capitalization of 26.34 B, debt of 7.79 M, and cash on hands of 848.4 M. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the BioArctic fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
26.19 B | 26.34 B | 7.79 M | 848.4 M |
BioArctic Investor Information
About 48.0% of the company shares are held by company insiders. The company last dividend was issued on the 10th of May 2019. Based on the measurements of operating efficiency obtained from BioArctic's historical financial statements, BioArctic AB is not in a good financial situation at the moment. It has a very high risk of going through financial straits in December.BioArctic Asset Utilization
The concept of asset utilization usually refers to the revenue earned for every dollar of assets a company currently reports. The current return on assets of BioArctic suggests not a very effective usage of assets in November.BioArctic Ownership Allocation
BioArctic holds a total of 73.73 Million outstanding shares. BioArctic AB retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Please note that no matter how many assets the company secures, if the real value of the firm is less than the current market value, you may not be able to make money on it.BioArctic Profitability Analysis
The company reported the revenue of 23.15 M. Net Loss for the year was (119.79 M) with profit before overhead, payroll, taxes, and interest of 155.53 M.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates BioArctic's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in BioArctic and how it compares across the competition.
About BioArctic Valuation
The stock valuation mechanism determines BioArctic's current worth on a weekly basis. Our valuation model uses a comparative analysis of BioArctic. We calculate exposure to BioArctic's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of BioArctic's related companies.BioArctic AB , a research intensive biopharmaceutical company, develops disease modifying treatments and diagnostics for neurodegenerative diseases in Sweden. BioArctic AB was founded in 1992 and is headquartered in Stockholm, Sweden. BioArctic is traded on Stockholm Stock Exchange in Sweden.
8 Steps to conduct BioArctic's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates BioArctic's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct BioArctic's valuation analysis, follow these 8 steps:- Gather financial information: Obtain BioArctic's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine BioArctic's revenue streams: Identify BioArctic's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research BioArctic's industry and market trends, including the size of the market, growth rate, and competition.
- Establish BioArctic's growth potential: Evaluate BioArctic's management, business model, and growth potential.
- Determine BioArctic's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate BioArctic's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Complementary Tools for BioArctic Stock analysis
When running BioArctic's price analysis, check to measure BioArctic's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy BioArctic is operating at the current time. Most of BioArctic's value examination focuses on studying past and present price action to predict the probability of BioArctic's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move BioArctic's price. Additionally, you may evaluate how the addition of BioArctic to your portfolios can decrease your overall portfolio volatility.
| CEOs Directory Screen CEOs from public companies around the world | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| ETFs Find actively traded Exchange Traded Funds (ETF) from around the world | |
| Portfolio Dashboard Portfolio dashboard that provides centralized access to all your investments | |
| Fundamentals Comparison Compare fundamentals across multiple equities to find investing opportunities |